



December 2, 2024

For Immediate Release

|                          |   |
|--------------------------|---|
| Company Name:            | Sumitomo Chemical Co., Ltd.   |
| Representative:          | Keiichi Iwata<br>President and Representative Director  |
| Securities Code:         | 4005  |
| Stock Exchange Listings: | Prime Section of the Tokyo Stock Exchange   |
| Inquiries:               | Shunji Kobayashi<br>General Manager<br>Corporate Communications Dept.<br>(Tel: +81-3-5201-0200) |

## **Notice Regarding the Recording of Other Operating Income in Consolidated Financial Statements and Extraordinary Income in Non-Consolidated Financial Statements due to the Transfer of Shares of a Consolidated Subsidiary**

At the Board of Directors meeting held on December 2, 2024, Sumitomo Chemical resolved to transfer all of the shares it holds in Nihon Medi-Physics Co., Ltd. (hereinafter “NMP”), a consolidated subsidiary of the Company, to GE HealthCare Ltd. (headquartered in Buckinghamshire, the United Kingdom), a subsidiary of GE HealthCare Technologies, Inc. (headquartered in Illinois, the United States; hereinafter “GE HealthCare”), as outlined below. Sumitomo Chemical expects to record other operating income in its consolidated financial statements and extraordinary income in its non-consolidated financial statements due to the share transfer, and hereby announces the details as follows. The share transfer is set to take place on March 31, 2025.

### **1. Reason for the Share Transfer**

Over the more than a half century since the founding of NMP in 1973, Sumitomo Chemical has engaged in the management of NMP and helped drive the business growth of the subsidiary, which has become a leading radiopharmaceuticals company in Japan. In 2004, GE Healthcare acquired 50% of the shares of NMP, and since then Sumitomo Chemical and GE Healthcare have engaged in the management of the subsidiary as equal partners.

Sumitomo Chemical held in-depth discussions with GE HealthCare about NMP’s future growth path. The Company has concluded that GE HealthCare, which is operating its business globally with an extensive portfolio of diagnostic agents and medical devices, is the best owner for NMP to achieve sustainable growth going forward and that it would be in the best interest of NMP to work to enhance its competitiveness and pursue opportunities for business expansion under GE HealthCare’s ownership. Accordingly, the Company has decided to implement the share transfer.

## **2. Overview of the Share Transfer**

|                        |   |
|------------------------|---|
| Company name:          | Nihon Medi-Physics Co., Ltd.  |
| Location:              | 3-4-10 Shinsuna, Koto-ku, Tokyo 136-0075, Japan   |
| Date of establishment: | March 1973  |
| Capital:               | 3,146 million yen   |
| Shareholding ratios:   | Sumitomo Chemical: 50%; GE HealthCare IVD (Netherlands) B.V. : 26%;<br>GE HealthCare Ltd.: 24%  |
| Scope of business:     | Research, development, manufacture, sales, and import and export of radiopharmaceuticals, diagnostic agents, therapeutic agents, and medical devices and related products |

## **3. Overview of the Transferee**

|               |  |
|---------------|--|
| Company name: | GE Healthcare Ltd.                           |
| Location:     | Buckinghamshire, the United Kingdom          |
| Established:  | February 1971                                |
| Capital:      | £707,549,967                                 |
| Business:     | Development and sales of diagnostic products |

## **4. Impact on Financial Results**

In its consolidated financial statements for the fourth quarter of the fiscal year ending March 31, 2025, Sumitomo Chemical expects to record a gain of approximately 30.0 billion yen from the share transfer in other operating income. In addition, in its non-consolidated financial statements for the fourth quarter of the fiscal year ending March 31, 2025, the Company expects to record a gain on sale of shares of subsidiaries and associates of approximately 25.0 billion yen in extraordinary income.

The impact of the above on the consolidated financial results was included in its financial forecast for the full year ending on March 31, 2025 announced on October 30, 2024, and therefore, there is no revision to the Company's financial forecast due to the share transfer.